A Review On: Novel Drug Delivery Technology Of Rituximab

Indrayuni, Ni Made Dwi and Tri E., Erfan and Irfan, Baharudin and Hati, Sari Kusuma and Abdullah, Siti Saharah (2021) A Review On: Novel Drug Delivery Technology Of Rituximab. World Journal of Pharmaceutical Research, 10 (2). ISSN 2277– 7105

[thumbnail of WJPR 19764.pdf]
WJPR 19764.pdf

Download (409kB) | Preview
Official URL / DOI: https://wjpr.net/dashboard/abstract_id/16103


Rituximab can be used for the treatment of severe rheumatoid arthritis, follicular lymphoma phase III-IV, follicular non-hodgkins lymphoma, chronic lymphocytic leukimia therapy, advance therapy of granulomatosis polyangiitis and microscopic polyitis. Rituximab is a two compartment with an average half-life of 87 ± 18 hours and a volume distribution of 1.3L. Administration of rituximab at a dose of 375 mg / m2 in 4 consecutive weeks can increase serum drug concentration in each administration by infusion. This review article focuses on biosimilar technology of rituximab was carried out by increasing the teraupetic mechanism and the response to the potential effects of binding B-mAB in NHL disease. The development of biosimilar rituximab approved by the FDA, namely ofatumab (anti CD20) and Obinutuzumab (mAb from rituximab with a different glucose group).

Item Type: Article
Uncontrolled Keywords: Rituximab, Biosimilar, NHL disease
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Postgraduate Programs > Master Program in Clinical Pharmacy
Depositing User: Ester Sri W. 196039
Date Deposited: 09 Mar 2021 07:50
Last Modified: 31 Mar 2021 02:39
URI: http://repository.ubaya.ac.id/id/eprint/39006

Actions (login required)

View Item View Item